Annotation Detail

Information

Associated Genes: ABL1
Associated Variants: ABL1 p.Thr334Ile (p.T334I) ABL1 p.Thr334Ile (p.T334I)
Associated Disease: chronic myeloid leukemia
Source Database: CIViC Evidence
Description: In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The T315I mutation was associated with resistance in 16 μM imatinib ( 15 clones, 45% of viable clones in this treatment), 5000 nM nilotinib (10 clones, 100%), and 25 nM dasatinib (32 clones, 100%) which were the highest concentrations used. T315I resistant clones were also found at all lower concentrations tested.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/6285
Gene URL: https://civic.genome.wustl.edu/links/genes/4
Variant URL: https://civic.genome.wustl.edu/links/variants/2
Rating: 3
Evidence Type: Predictive
Disease: Chronic Myeloid Leukemia
Evidence Direction: Supports
Drug: Nilotinib,Imatinib Mesylate,Dasatinib
Evidence Level: D
Clinical Significance: Resistance
Pubmed: 16772610

Drugs